Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

被引：63
|
作者：
Leonard, JP
Link, BK
机构：
[1] Cornell Univ, Weill Med Coll, Ctr Lymphoma & Myeloma, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA
[3] New York Presbyterian Hosp, New York, NY USA
[4] Univ Iowa, Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA USA
[5] Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA
来源：
SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 01期
关键词：
D O I：
10.1053/sonc.2002.30149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81 / 86
页数：6
相关论文
共 50 条
  • [21] Fractionated-dose radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody (epratuzumab).: Interim results.
    Chatal, JF
    Harousseau, JL
    Truemper, LH
    Meller, J
    Pfreundschuh, M
    Kirsch, CM
    Naumann, R
    Kropp, J
    Wegener, WA
    Ding, C
    Horak, ID
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 408A - 408A
  • [22] Combination monoclonal antibody therapy for lymphoma: Treatment with epratuzumab (anti-CD22) and rituximab (anti-CD20) is well tolerated.
    Leonard, JP
    Coleman, M
    Matthews, JC
    Fiore, JM
    Dosik, A
    Kapushoc, H
    Kin, E
    Cesano, A
    Wegener, WA
    Goldenberg, DM
    BLOOD, 2001, 98 (11) : 844A - 844A
  • [23] Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody
    Tsai, DE
    Maillard, I
    Schuster, SJ
    Nasta, SD
    Porter, DL
    Klumpp, TR
    Goldenberg, DM
    Luger, SM
    Alavi, A
    Sharkey, RM
    Hartzell, KB
    Stadtmauer, EA
    CLINICAL LYMPHOMA, 2003, 4 (01): : 56 - 59
  • [24] Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkin's lymphoma (NHL) patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab.
    Hajjar, G
    Sharkey, RM
    Burton, J
    Schuster, S
    Czuczman, M
    Lamonica, D
    Chatal, JF
    Alavi, A
    Stadtmauer, EA
    Leonard, J
    Coleman, M
    Plutchock, J
    Brenner, AI
    Goldenberg, DM
    BLOOD, 2001, 98 (11) : 611A - 611A
  • [25] Mechanisms of anti-lymphoma effects of the humanized anti-CD22 monoclonal antibody, epratuzumab, and combination studies with anti-CD20 MAbs.
    Stein, R
    Qu, ZX
    Chen, S
    Rosario, A
    Horak, ID
    Hansen, HJ
    Goldenberg, DM
    BLOOD, 2003, 102 (11) : 298B - 299B
  • [26] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma (vol 10, pg 108, 1998)
    White, CA
    MINERVA BIOTECNOLOGICA, 1999, 11 (02) : 160 - 160
  • [27] The in vitro effects of immobilized epratuzumab, a non-blocking anti-CD22 humanized monoclonal antibody, on malignant B cells
    Gupta, Pankaj
    Michel, Rosana B.
    Goldenberg, David M.
    Change, Chien-Hsing
    CANCER RESEARCH, 2012, 72
  • [28] Enhancement in anti-tumor activity of Rituximab when combined with Epratuzumab or Apolizumab (Hu1D10) in a B-cell lymphoma severe combined immunodeficiency (SCID) mouse model.
    Hernandez-Ilizaliturri, F
    Gada, P
    Repasky, EA
    Czuczman, MS
    BLOOD, 2002, 100 (11) : 158A - 158A
  • [29] Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
    Witzig, Thomas E.
    Tomblyn, Michael B.
    Misleh, Jamal G.
    Kio, Ebenezer A.
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    HAEMATOLOGICA, 2014, 99 (11) : 1738 - 1745
  • [30] Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia.
    Hegde, U
    White, T
    Stetler-Stevenson, M
    Marti, G
    Janik, J
    Pittaluga, S
    Kingma, D
    Steinberg, S
    Cheson, B
    Jaffe, ES
    Wilson, WH
    BLOOD, 2002, 100 (11) : 358A - 358A
12345